KPV

KPV is a tripeptide made of lysine, proline and valine. It is the C-terminal fragment of alpha-MSH, a naturally occurring melanocortin peptide. Research has focused on its anti-inflammatory profile, particularly in the gut, and on activity that appears independent of the pigmentation signaling associated with the parent alpha-MSH molecule. Current evidence comes largely from cell culture and animal model studies.

Research investigates KPV for its ability to enter cells and interfere with intracellular inflammatory signaling, rather than acting primarily at a surface receptor. Studies have examined its effects on NF-κB-associated signaling, and one keratinocyte study reported modulation of the MAPK/NF-κB pathway along with regulation of oxidative stress. A liver cell study described ROS-dependent effects on the PPARγ pathway. These mechanisms have been characterized in laboratory models.

The most prominent research area is colonic inflammation, including animal work in which a KPV-binding hydrogel was studied for restoring the gut mucosal barrier in an inflamed colon. Other studies have examined fine dust-induced inflammation and apoptosis in keratinocytes, and hepatic lipid accumulation in HepG2 cells. These findings are preclinical and have not been confirmed in controlled human trials.

Human safety data for KPV are limited. The available studies are cell culture and animal investigations, and adverse events are not summarized in these cited studies. Because the evidence base is preclinical, no established human safety profile, contraindication list, or interaction data can be described with confidence. KPV supplied by CoreX is intended for laboratory research use only.

Research protocols have used 200–500 mcg per administration, once daily in the morning under fasted conditions, in 8-week blocks followed by 4 weeks off, with subcutaneous administration described. These figures describe research protocols only and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference.